Active ingredientMavoglurantCat. No. P-M013-001CAS 543906-09-8Family · Pharmaceutical analytical standards
Mavoglurant
An investigational antagonist of the metabotropic glutamate receptor mGluR5, studied from the 2000s in fragile X syndrome, levodopa-induced dyskinesia and obsessive-compulsive disorder; development for fragile X was stopped in 2014. This family brings together the active ingredient and labelled standards.
Did you know?Had the trials succeeded, it would have been the first drug to target the underlying mechanism of fragile X syndrome rather than just its symptoms.
Go to the active ingredient →Active ingredientMavoglurantCat. No. P-M013-001CAS 543906-09-8
Isotopically labelledMavoglurant-d3Cat. No. P-M013-002No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.